Atrial Cardiopathy and Cryptogenic Stroke

Yuji Kato1, Shinichi Takahashi1

  • 1Department of Neurology and Cerebrovascular Medicine, Saitama Medical University International Medical Center, Hidaka, Japan.

Frontiers in Neurology
|March 11, 2022
PubMed

Insights

Atrial cardiopathy, characterized by atrial dysfunction, can cause stroke before atrial fibrillation (AF) develops. Identifying this condition may prevent cryptogenic strokes.

Area of Science:

  • Cardiology
  • Neurology
  • Pathophysiology

Background:

  • Pathophysiological advances suggest atrial substrate abnormalities can lead to embolic stroke independently of atrial fibrillation (AF).
  • Atrial cardiopathy, defined as atrial structural and functional disorders, may precede AF development and contribute to stroke risk.
  • Cryptogenic stroke, a stroke of unknown origin, may be linked to underlying atrial cardiopathy.

Purpose of the Study:

  • To provide a comprehensive overview of atrial cardiopathy and its association with cryptogenic stroke.
  • To summarize current knowledge on the pathogenesis, biomarkers, and therapeutic interventions for atrial cardiopathy.
  • To explore the potential of atrial cardiopathy as a therapeutic target for stroke prevention.

Main Methods:

  • A narrative review of studies identified through a PubMed database search.
  • Synthesis of recent findings on atrial cardiopathy, including its pathophysiology, diagnostic markers, and clinical implications.
  • Analysis of the relationship between atrial cardiopathy and cryptogenic stroke, and potential treatment strategies.

Main Results:

  • Atrial cardiopathy can cause embolic strokes before the clinical manifestation of AF.
  • Promising biomarkers for atrial cardiopathy include P-wave terminal force in lead V1, N-terminal pro-brain natriuretic peptide, and left atrial enlargement.
  • Atrial cardiopathy is considered a spectrum disorder, and its role as a therapeutic target is under investigation.

Conclusions:

  • Atrial cardiopathy represents a significant substrate for embolic stroke, potentially explaining cryptogenic strokes in some patients.
  • Further research is needed to establish optimal diagnostic criteria and therapeutic targets for atrial cardiopathy.
  • The ARCADIA trial is investigating atrial cardiopathy as a target for anticoagulation therapy to prevent stroke.

Related Concept Videos

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
191
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
64
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
68
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
71
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
69
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
96